Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
Toolkit Webinar CRM Triad Post-Survey
I am a(n)…
[ Required ]
Select...
MD/DO
NP/RN
PA
Other
How many years have you been in practice?
[ Required ]
Select...
1-5
6-10
11-15
16-20
Over 20
What is your practice setting?
[ Required ]
Select...
Solo Practice
Group Practice
Hospital
Clinic
Academic
Other
Number of patients seen per month with...
Cardiovascular Disease?
[ Required ]
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Diabetes?
[ Required ]
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Kidney Disease (CKD)?
[ Required ]
Select...
1-10
11-20
21-30
31-40
41-50
Over 50
Please rate the following:
Degree to which your educational expectations were met
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Relevance to your practice
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Effective faculty presenter
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Overall Presentation
[ Required ]
Select...
Excellent
Above Average
Average
Fair
Poor
Please rate the degree to which the Learning Objectives were met.
Apply strategies for diagnosing T2D, HF, and CKD early in the disease course to slow progression and reduce adverse outcomes
[ Required ]
Select...
Completely
Mostly
Somewhat
Not at all
Incorporate evidence-based, guideline-recommended therapeutic agents for treating CRM conditions across the spectrum of disease
[ Required ]
Select...
Completely
Mostly
Somewhat
Not at all
Engage the multidisciplinary heath care team to promote optimal care of CRM disease across settings
[ Required ]
Select...
Completely
Mostly
Somewhat
Not at all
Agree or Disagree?
The presentation was fair and balanced, free of commercial bias.
[ Required ]
Select...
YES
NO
I feel more competent as a result of the presentation.
[ Required ]
Select...
YES
NO
The presentation was scientifically rigorous.
[ Required ]
Select...
YES
NO
The content contributed valuable information that will assist in improving patient outcomes
[ Required ]
Select...
Strongly Agree
Agree
Unsure
Disagree
Strongly Disagree
Will you change your practice behaviors as a result of the presentation?
[ Required ]
Select...
Absolutely
Probably
Unsure
Unlikely
No
What will you change?
[ Required ]
Change the medications I prescribe
Adhere more closely to ADA Standards of Care
Prescribe more SGLT2 inhibitors
Educate my colleagues
Educate my patients
Screen for and diagnose CKD earlier
Screen patients with diabetes for albuminuria
Be more aware of links between cardiovascular, renal and metabolic disorders
Other
If Other
Because you are likely to make changes to your practice behaviors, you are eligible to qualify for T2P (Translation to Practice) Credit, an additional 2.0 Credits. Please provide your email address below and we will send you a link to a followup survey in six weeks. If you have made changes to your practice behaviors, you will receive those additional two credits.
[ Invalid e-mail address ]
What barriers to change do you foresee?
[ Required ]
Cost
Insurance Coverage
Formulary
Patient Compliance
Time with Patient
Other
If Other
What was your level of knowledge on this subject?
Before the presentation
[ Required ]
Select...
None
Little
Some
Considerable
Expert
After the presentation
[ Required ]
Select...
None
Little
Some
Considerable
Expert
Which of the following is true about screening for CKD in patients with diabetes?
[ Required ]
Cystatin C and creatine testing are preferred for initial CKD screening
Only checking eGFR is recommended since it independently predicts CVD mortality
Only checking UACR is recommended since it independently predicts CVD mortality
Checking eGFR and UACR is recommended since both independently predict CVD mortality
Certain agents from which of the following drug classes have FDA approval for indications of T2D, HF(regardless of injection fraction), and CKD(with or without diabetes)?
[ Required ]
ACE inhibitors
SGLT2 inhibitors
GLP-1 receptor agonists
Nonsteroidal MRAs
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
What do you need to learn more about on this topic?
Submit